N,N-dimethyl-2-(4'-(ethan-2-ol)-2'-nitrophenylthio)benzylamine | 627488-52-2

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: N,N-dimethyl-2-(4'-(ethan-2-ol)-2'-nitrophenylthio)benzylamine
• 英文别名: 2-[4-[2-[(Dimethylamino)methyl]phenyl]sulfanyl-3-nitrophenyl]ethanol
• CAS: 627488-52-2
• 化学式: C₁₇H₂₀N₂O₃S
• 分子量: 332.423
• InChiKey: AAKRHOXBGJWJBG-UHFFFAOYSA-N

物化性质

• 沸点：
  451.8±45.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  94.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N,N-dimethyl-2-(4'-(ethan-2-ol)-2'-nitrophenylthio)benzylamine 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以19%的产率得到2-[3-Amino-4-(2-dimethylaminomethyl-phenylsulfanyl)-phenyl]-ethanol
  参考文献：
  名称：

  N，N-二甲基-2-（2'-氨基-4'-取代的苯硫基）苄胺的合成，体外表征和放射性标记：潜在的候选物质，作为选择性5-羟色胺转运体的配体。

  摘要：

  制备了一系列在4'-苯基位置取代的N，N-二甲基-2-（2'-氨基-4'-碘苯硫基）苄胺的N，N-二甲基化和N-单甲基化类似物，并进行了体外评估血清素转运蛋白（SERT）的选择性。制备了几种衍生物，其中4'-位未被取代的13和33a或被甲基14a和33b，乙烯基14b和34，乙基16和35，羟甲基20和41，羟乙基22，氟乙基23，羟丙基27和氟丙基取代28.使用[（3）H]西酞普兰，[（3）H] WIN 35,428或[（125）I] RTI在稳定表达转染的人类SERT，多巴胺转运蛋白（DAT）和去甲肾上腺素转运蛋白（NET）的细胞中竞争结合-55和[（3）H] nisoxetine分别显示出以下顺序的SERT亲和力（K（i）（nM））：14a（0.25）> 16（0.49）> 20（0.57）> 14b（1.12）> 13（1.59）> 33b（1.94）= 35（2.04）>> 23（8

  DOI：

  10.1021/jm050079o
• 作为产物：
  描述：

  硫代水杨酸 在 氯化亚砜 、 硼烷四氢呋喃络合物 、 铜 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 N,N-dimethyl-2-(4'-(ethan-2-ol)-2'-nitrophenylthio)benzylamine
  参考文献：
  名称：

  Fluorinated Diaryl Sulfides as Serotonin Transporter Ligands:  Synthesis, Structure−Activity Relationship Study, and in Vivo Evaluation of Fluorine-18-Labeled Compounds as PET Imaging Agents

  摘要：

  A series of new, fluorine-containing substituted diphenyl sulfides was synthesized to serve as candidate ligands for positron emission tomography (PET) imaging of the serotonin transporter (SERT) and to further probe the structure-activity relationship (SAR) of this class of compounds. Candidate compounds were assayed for their affinities to the monoamine transporters (SERT, norepinephrine transporter (NET), and dopamine transporter (DAT)) in competitive binding experiments in vitro using cloned human transporters. From these in vitro assays, four compounds (7c-f) were chosen for further evaluation. All four compounds have nanomolar affinity for SERT (K-i 1.46 nM, 1.04 nM,1.83 nM, and 3.58 nM for 7c, 7d, 7e, and 7f, respectively). The F-18-labeled compounds, 16 and 18a-c, were prepared via a two-step radiosynthesis. Biodistribution studies in rats indicated that the F-18-labeled compounds localized in brain regions with high concentrations of SERT. Furthermore, competition experiments demonstrated that the binding of these radioligands in the rat brain was saturable, specific, and selective to SERT. Specific binding in the rat hypothalamus peaked at 5.6 for ligand 16 and 4.4 for 18b at 90 min after radioactivity administration. For ligand 18a, this same ratio was 8.4 at 120 min postinjection, while compound 18c displayed a lower-specific binding ratio of 2.4. In summary, four F-18-labeled ligands were prepared and evaluated as candidate PET imaging agents for SERT. Among these four ligands, three appear to be promising radioligands suitable for the labeling of SERT in vivo, with 18a providing a higher specific binding in vivo than 16 or 18b.

  DOI：

  10.1021/jm0400808

文献信息

• Huang, Y.; Bae, S.-A.; Zhu, Z., Journal of labelled compounds and radiopharmaceuticals, 2001, vol. 44, p. S18 - S20
  作者：Huang, Y.、Bae, S.-A.、Zhu, Z.、Guo, N.、Hwang, D. R.、Laruelle, M.

  DOI：——

  日期：——